EKO International Corp - Summary of NeuroVasc Clinical Inc.'s (NVCI) Business

BURLINGTON, ON, Sept. 26, 2012 /PRNewswire/ - One of the greatest challenge facing North American health care today is diabetes. It is estimated that there are 60 million diabetics in North American in 2012 and that number is climbing rapidly. Approximately 65% of diabetics will develop peripheral neuropathy, a painful and often irreversible condition affecting both lower limbs. It begins as tingling and mild pain in the feet and eventually it becomes painless as the nerve function is compromised and sensation is lost. The loss of nerve function and decreased vascularity in the lower limb makes the patient susceptible to ulcers and wounds on the foot that will heal very slowly if at all. This opens up the risk for infection and greatly increases the likelihood of amputation. The cost in human terms and in financial terms to the health care system is staggering. It is estimated there is an amputation every 30 seconds in North America.

NeuroVasc Clinical Inc. has brought a solution to the North American market place. The patented technology called FREMS is an FDA and Health Canada approved device that uses a patented electrical frequency and duty cycle to stimulate blood vessel re-growth and tissue regeneration in tissue that has compromised nerve and blood vessel function. The patient is treated 10 times once daily for 40 minutes and the effects on the tissue will last up to 18 month depending on the overall health of the patient. Thus this treatment becomes part of the maintenance of the lower limb for the diabetic patient as they age and will be a key player in the prevention of painful neuropathy and the development of dangerous wounds. 

Each FREMS device can treat approx.  8-10 patients a day.
The sale of each FREMS device will generate approx. $ 8,000 of gross profit for EKO
Consumable supplies for each treatment will generate approx. $3.00 of gross profit for EKO

NeuroVasc Clinical will be partnering with leading doctors and clinics in North America to provide this service locally. Training and patient education will be provided centrally by NeuroVasc Clinical and treatment will be provided at clinics certified by NeuroVasc Clinical locally. 

Each FREMS device is expected to generate between $1,000 and $1,500 gross income per day for the clinics which are recommended to operate 3-5 devices per clinic. 

NeuroVasc Clinical is committed to seeking out world class partners and helping them provide this invaluable service to the diabetic population to prevent unwanted illness and even early mortality.

SOURCE EKO INTERNATIONAL CORP.